Innovotech Inc. specializes in providing assay kits for microbial biofilm research in the healthcare biotechnology sector. While the company has a solid liquidity position with a current ratio of 2.07 and no debt, it faces significant profitability challenges, evident in its low gross margin of 8.6% and negative net margin of -96.2%. This raises concerns about its operational efficiency and long-term viability. The market cap of $3.54M suggests limited investor confidence, reflecting the need for improved financial performance despite its niche product offering.
Loading financial metrics...
Company is burning $138K per quarter with $375K in cash. Approximately 2.7 quarters of runway at current burn rate.
Gross profit margin declined from 53.5% to 39.4% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-783K over the last year, representing 21.1% of revenue.
Exceptional revenue growth of 73.6% YoY demonstrates strong market demand and competitive positioning.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Low debt-to-revenue ratio of 0.0% indicates conservative financial management.
Strong liquidity position with current ratio of 2.1x.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q2 (June 30, 2026)